Books and Book Chapters

      Experimental Models of Environmental Tobacco Smoke Exposure: Structural and Functional Changes in Epithelial Cells of the Respiratory Tract

      Schlage, W. K.; Teredesai, A.
      Date published
      Jun 15, 2000
      DOI
      10.1201/9781420042245
      ISBN
      9780429124587
      Published in
      Environmental Tobacco Smoke 
      Editors
      Witten, M. L.
      Link to publication
      Topic
      Summary

      The health effects of exposure to environmental tobacco smoke (ETS) have been the subject of numerous literature reviews during the past decade. Most of the investigations, which concluded that exposure to ETS may increase the risk of lung cancer, chronic obstructive pulmonary disease (COPD), cardiovascular disease, intrauterine growth retardation, and Sudden Infant Death Syndrome, are based on epidemiological studies (cf. References 1 to 6). In a notice of proposed rulemaking (NPR), the Occupational Safety and Health Administration (OSHA) concluded that ETS “may produce mucous membrane irritation, pulmonary, cardiovascular, reproductive and carcinogenic effects” and that ETS “presents a serious health risk to workers.”

      Related Publications

      Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters

      Pre-clinical Toxicology

      Quantification and mapping of alkylation in the human genome reveal single nucleotide resolution precursors of mutational signatures

      Pre-clinical Toxicology

      An in vitro evaluation of e-vapor products: The contributions of chemical adulteration, concentration, and device power

      Pre-clinical Toxicology

      Tobacco heating system has less impact on bone metabolism than cigarette smoke

      Pre-clinical Toxicology

      Novel α7 nicotinic acetylcholine receptor modulators as potential antitussive agents

      Pre-clinical Toxicology

      Differentiating the neuropharmacological properties of nicotinic acetylcholine receptor-activating alkaloids

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.